Search

Your search keyword '"Pun, Patrick H."' showing total 183 results
Start Over Author "Pun, Patrick H."
183 results on '"Pun, Patrick H."'

8. Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function

Author

Pun, Patrick H, Sheng, Shubin, Sanders, Gillian, DeVore, Adam D, Friedman, Daniel, Fonarow, Gregg C, Heidenreich, Paul A, Yancy, Clyde W, Hernandez, Adrian F, and Al-Khatib, Sana M

Subjects
Clinical Research, Kidney Disease, Heart Disease, Cardiovascular, Renal and urogenital, Aged, Biomarkers, Cardiac Resynchronization Therapy, Defibrillators, Implantable, Demography, Electric Countershock, Female, Heart Failure, Hospitalization, Humans, Kidney Function Tests, Male, Middle Aged, Practice Guidelines as Topic, Renal Insufficiency, Treatment Outcome, United States, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology
Abstract

Implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy (CRT) reduce mortality in many patients with heart failure (HF), but the current use and effectiveness of ICD/CRT in patients with chronic kidney disease (CKD) are uncertain. We examined associations between kidney function and guideline-recommended prescription of ICD/CRT in the Get With The Guidelines-Heart Failure registry, a performance improvement program for hospitalized patients with HF. We compared differences in ICD and CRT prescription between the following categories of estimated glomerular filtration rate (eGFR; mL/min/1.73 m2): ≥60, 59 to 30,

Published
2017

10. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study

Author

Pun, Patrick H, Hellkamp, Anne S, Sanders, Gillian D, Middleton, John P, Hammill, Stephen C, Al-Khalidi, Hussein R, Curtis, Lesley H, Fonarow, Gregg C, and Al-Khatib, Sana M

Subjects
Cardiovascular, Kidney Disease, Clinical Research, Heart Disease, Prevention, Renal and urogenital, Good Health and Well Being, Aged, Aged, 80 and over, Death, Sudden, Cardiac, Defibrillators, Implantable, Female, Heart Failure, Humans, Incidence, Kidney Failure, Chronic, Male, Middle Aged, Primary Prevention, Propensity Score, Proportional Hazards Models, Registries, Renal Dialysis, Retrospective Studies, cardiovascular disease, defibrillator, dialysis, end-stage kidney disease, sudden cardiac death, Clinical Sciences, Urology & Nephrology
Abstract

BackgroundSudden cardiac death is the leading cause of death among end-stage kidney disease patients (ESKD) on dialysis, but the benefit of primary prevention implantable cardioverter defibrillators (ICDs) in this population is uncertain. We conducted this investigation to compare the mortality of dialysis patients receiving a primary prevention ICD with matched controls.MethodsWe used data from the National Cardiovascular Data Registry's ICD Registry to select dialysis patients who received a primary prevention ICD, and the Get with the Guidelines-Heart Failure Registry to select a comparator cohort. We matched ICD recipients and no-ICD patients using propensity score techniques to reduce confounding, and overall survival was compared between groups.ResultsWe identified 108 dialysis patients receiving primary prevention ICDs and 195 comparable dialysis patients without ICDs. One year (3-year) mortality was 42.2% (68.8%) in the ICD registry cohort compared with 38.1% (75.7%) in the control cohort. There was no significant survival advantage associated with ICD [hazard ratio (HR) 0.87, 95% confidence interval (CI) 0.66-1.13, log-rank P = 0.29]. After propensity matching, our analysis included 86 ICD patients and 86 matched controls. Comparing the propensity-matched cohorts, 1 year (3 years) mortality was 43.4% (74.0%) in the ICD cohort and 39.7% (76.6%) in the control cohort; there was no significant difference in mortality outcome between groups (HR = 0.94, 95% CI: 0.67-1.31, log-rank P = 0.71).ConclusionsWe did not observe a significant association between primary prevention ICDs and reduced mortality among ESKD patients receiving dialysis. Consideration of the potential risks and benefits of ICD implantation in these patients should be undertaken while awaiting the results of definitive clinical trials.

Published
2015

11. Barriers and Facilitators to Performing Cardiopulmonary Resuscitation During Treatment in Outpatient Hemodialysis Clinics: A Qualitative Study

Author

Hofacker, Samuel A., Fish, Laura J., Blewer, Audrey L., and Pun, Patrick H.

Subjects
Cardiac arrest -- Care and treatment, Hemodialysis patients -- Care and treatment, Dialysis facilities -- Quality management, Cardiopulmonary resuscitation -- Methods, Health
Abstract

Cardiac arrest is the leading cause of death among patients receiving hemodialysis, and major deficiencies exist in hemodialysis staff-provided cardiopulmonary resuscitation (CPR). Our study aimed to identify factors influencing CPR delivery in the outpatient hemodialysis clinic. Through content analysis of in-depth interviews with 10 staff members of a hemodialysis clinic, we identified three broad themes regarding barriers and facilitators to performing CPR in the hemodialysis clinic: 1) physical and environmental challenges regarding the layout of the clinic; 2) uncertainty about optimal in-clinic CPR procedures, particularly concerning patient positioning and dealing with the hemodialysis machine; and 3) benefit of continuous improvement programs, including hemodialysis-specific protocols, hands-on training, and pre-defined team roles. Our findings call for further investigation of optimal in-clinic resuscitation procedures to inform hemodialysis clinic CPR protocols and hemodialysis staff training. Key Words: CPR, resuscitation, hemodialysis, cardiac arrest, safety., (CE) 1.2 contact hours More than 725,000 people have kidney failure in the United States, and over 450,000 receive maintenance hemodialysis. In these patients, cardiac arrest is the leading cause [...]

Published
2020
Full Text
View/download PDF

12. Association of Acute Kidney Injury and Cardiovascular Disease Following Percutaneous Coronary Intervention: Assessment of Interactions by Race, Diabetes, and Kidney Function

Author

Lunyera, Joseph, primary, Clare, Robert M., additional, Chiswell, Karen, additional, Scialla, Julia J., additional, Pun, Patrick H., additional, Thomas, Kevin L., additional, Starks, Monique A., additional, Mohottige, Dinushika, additional, Boulware, L. Ebony, additional, and Diamantidis, Clarissa J., additional

Published
2023
Full Text
View/download PDF

14. The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study

Author

Assimon, Magdalene M, Pun, Patrick H, Al-Khatib, Sana M, Brookhart, Maurice Alan, Gaynes, Bradley N, Winkelmayer, Wolfgang C, and Flythe, Jennifer E

Subjects
Transplantation, Citalopram, United States, Cohort Studies, Paroxetine, Death, Sudden, Cardiac, Renal Dialysis, Fluvoxamine, Nephrology, Dialysis Solutions, Fluoxetine, Sertraline, Case-Control Studies, Potassium, Humans, Original Article, Selective Serotonin Reuptake Inhibitors
Abstract

Background Hypokalemia is a risk factor for drug-induced QT prolongation. Larger serum-to-dialysate potassium gradients during hemodialysis (HD) may augment the proarrhythmic risks of selective serotonin reuptake inhibitors (SSRIs). Methods We conducted a cohort study using 2007–2017 data from the United States Renal Data System and a large dialysis provider to examine if the serum-to-dialysate potassium gradient modifies SSRI cardiac safety. Using a new-user design, we compared 1-year sudden cardiac death (SCD) risk among HD patients newly treated with higher (citalopram, escitalopram) versus lower (fluoxetine, fluvoxamine, paroxetine, sertraline) QT-prolonging potential SSRIs, overall and stratified by baseline potassium gradient (≥4 versus Results The study included 25 099 patients: 11 107 (44.3%) higher QT-prolonging potential SSRI new users and 13 992 (55.7%) lower QT-prolonging potential SSRI new users. Overall, higher versus lower QT-prolonging potential SSRI use was not associated with SCD [weighted HR 1.03 (95% CI 0.86–1.24)]. However, a greater risk of SCD was associated with higher versus lower QT-prolonging potential SSRI use among patients with baseline potassium gradients ≥4 mEq/l but not among those with gradients Conclusions The serum-to-dialysate potassium gradient may modify the association between higher versus lower QT-prolonging SSRI use and SCD among people receiving HD. Minimizing the potassium gradient in the setting of QT-prolonging medication use may be warranted.

Published
2022

16. letter to the editor

Author

Assimon, Magdalene M., primary, Pun, Patrick H., additional, Wang, Lily, additional, Al-Khatib, Sana M., additional, Brookhart, M. Alan, additional, Weber, David J., additional, Winkelmayer, Wolfgang C., additional, and Flythe, Jennifer E., additional

Published
2022
Full Text
View/download PDF

20. Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death in CKD: A Meta-analysis of Patient-Level Data From 3 Randomized Trials

Author

Pun, Patrick H., Al-Khatib, Sana M., Han, Joo Yoon, Edwards, Rex, Bardy, Gust H., Bigger, J. Thomas, Buxton, Alfred E., Moss, Arthur J., Lee, Kerry L., Steinman, Richard, Dorian, Paul, Hallstrom, Al, Cappato, Riccardo, Kadish, Alan H., Kudenchuk, Peter J., Mark, Daniel B., Hess, Paul L., Inoue, Lurdes Y.T., and Sanders, Gillian D.

Published
2014
Full Text
View/download PDF

21. PPIs may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis

Author

Assimon, Magdalene M., Pun, Patrick H., Al-Khatib, Sana M., Brookhart, M. Alan, Gaynes, Bradley N., Winkelmayer, Wolfgang C., and Flythe, Jennifer E.

Subjects
Adult, Death, Sudden, Cardiac, Escitalopram, Renal Dialysis, Sertraline, Humans, Proton Pump Inhibitors, Citalopram, Article, Antidepressive Agents, Selective Serotonin Reuptake Inhibitors, Retrospective Studies
Abstract

PURPOSE: Polypharmacy is common in the hemodialysis population and increases the likelihood that patients will be exposed to clinically significant drug-drug interactions. Concurrent use of proton pump inhibitors (PPIs) with citalopram or escitalopram may potentiate the QT-prolonging effects of these selective serotonin reuptake inhibitors through pharmacodynamic and/or pharmacokinetic interactions. METHODS: We conducted a retrospective cohort study using data from the U.S. Renal Data System (2007–2017) and a new-user design to examine the differential risk of sudden cardiac death (SCD) associated with citalopram/escitalopram initiation vs. sertraline initiation in the presence and absence of PPI use among adults receiving hemodialysis. We studied 72,559 patients: 14,983 (21%) citalopram/escitalopram initiators using a PPI; 26,503 (36%) citalopram/escitalopram initiators not using a PPI; 10,779 (15%) sertraline initiators using a PPI; and 20,294 (28%) sertraline initiators not using a PPI (referent). The outcome of interest was 1-year SCD. We used inverse probability of treatment weighted survival models to estimate weighted hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: Compared with sertraline initiators not using a PPI, citalopram/escitalopram initiators using a PPI had the numerically highest risk of SCD (HR [95% CI] = 1.31 [1.11–1.54]), followed by citalopram/escitalopram initiators not using a PPI (HR [95% CI] = 1.22 [1.06–1.41]). Sertraline initiators using a PPI had a similar risk of SCD compared with those not using a PPI (HR [95% CI] = 1.03 [0.85–1.26]). CONCLUSIONS: Existing PPI use may elevate the risk of SCD associated with citalopram or escitalopram initiation among hemodialysis patients.

Published
2022

23. modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study.

Author

Assimon, Magdalene M, Pun, Patrick H, Al-Khatib, Sana M, Brookhart, Maurice Alan, Gaynes, Bradley N, Winkelmayer, Wolfgang C, and Flythe, Jennifer E

Subjects
*SEROTONIN uptake inhibitors, *HYPOKALEMIA, *POTASSIUM, *CARDIAC arrest, *SEROTONIN syndrome, *HEMODIALYSIS
Abstract

Background Hypokalemia is a risk factor for drug-induced QT prolongation. Larger serum-to-dialysate potassium gradients during hemodialysis (HD) may augment the proarrhythmic risks of selective serotonin reuptake inhibitors (SSRIs). Methods We conducted a cohort study using 2007–2017 data from the United States Renal Data System and a large dialysis provider to examine if the serum-to-dialysate potassium gradient modifies SSRI cardiac safety. Using a new-user design, we compared 1-year sudden cardiac death (SCD) risk among HD patients newly treated with higher (citalopram, escitalopram) versus lower (fluoxetine, fluvoxamine, paroxetine, sertraline) QT-prolonging potential SSRIs, overall and stratified by baseline potassium gradient (≥4 versus <4 mEq/l). We used inverse probability of treatment-weighted survival models to estimate weighted hazard ratios (HRs) and 95% confidence intervals (CIs) and conducted a confirmatory nested case–control study. Results The study included 25   099 patients: 11   107 (44.3%) higher QT-prolonging potential SSRI new users and 13   992 (55.7%) lower QT-prolonging potential SSRI new users. Overall, higher versus lower QT-prolonging potential SSRI use was not associated with SCD [weighted HR 1.03 (95% CI 0.86–1.24)]. However, a greater risk of SCD was associated with higher versus lower QT-prolonging potential SSRI use among patients with baseline potassium gradients ≥4 mEq/l but not among those with gradients <4 mEq/l [weighted HR 2.17 (95% CI 1.16–4.03) versus 0.95 (0.78–1.16)]. Nested case–control analyses yielded analogous results. Conclusions The serum-to-dialysate potassium gradient may modify the association between higher versus lower QT-prolonging SSRI use and SCD among people receiving HD. Minimizing the potassium gradient in the setting of QT-prolonging medication use may be warranted. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. eGFR Variability in Patients with Heart Failure and Chronic Kidney Disease

Author

Hein, Aaron M., Scialla, Julia J., Sun, Jie-Lena, Greene, Stephen J., Shaw, Linda K., Chiswell, Karen, Pun, Patrick H., and Mentz, Robert J.

Subjects
Heart Failure, Disease Progression, Humans, Renal Insufficiency, Chronic, Coronary Angiography, Article, Glomerular Filtration Rate
Abstract

BACKGROUND: Greater variability in estimated glomerular filtration rate (eGFR) is associated with higher mortality in patients with chronic kidney disease (CKD). Heart failure (HF) is common in CKD and may increase variability through changes in hemodynamic and volume regulation. We sought to determine if patients with versus without HF have higher kidney function variability in CKD, and to define the association with mortality. METHODS: Patients undergoing coronary angiography from 2003–2013 with eGFR

Published
2021

36. CONTRIBUTORS

Author

Acchiardo, Sergio R., primary, Agarwal, Rajiv, additional, Al-Uzri, Amira, additional, Anderson, Connie, additional, Armenti, Vincent T., additional, Ash, Stephen R., additional, Avram, Morrell Michael, additional, Bellasi, Antonio, additional, Benfield, Mark R., additional, Bennett, William M., additional, Berns, Jeffrey S., additional, Besarab, Anatole, additional, Blagg, Christopher R., additional, Block, Geoffrey A., additional, Boccardo, Paola, additional, Bolton, W. Kline, additional, Brandt, Mary L., additional, Brewer, Eileen D., additional, Brophy, Patrick D., additional, Brown, Warren S., additional, Bunnapradist, Suphamai, additional, Burkart, John M., additional, Campese, Vito M., additional, Caruana, Ralph J., additional, Cass, Darrell L., additional, Chadha, Vimal, additional, Chan, Christopher T., additional, Charytan, Chaim, additional, Clark, William R., additional, Collins, Allan J., additional, Cramer, Carl H., additional, Crawford-Bonadio, Terri L., additional, Freitas, Declan de, additional, Diaz-Buxo, José A., additional, Dinwiddie, Lesley C., additional, Ellis, Eileen N., additional, Englund, Janet A., additional, Fabrizi, Fabrizio, additional, Feinfeld, Donald A., additional, Foulks, Charles Jerome, additional, Fouque, Denis, additional, Galbusera, Miriam, additional, Gao, Dayong, additional, Gennari, F. John, additional, Giullian, Jeffrey, additional, Goldstein, Stuart L., additional, Gonzalez, Esther A., additional, Goodman, William G., additional, Gotch, Frank A., additional, Haghighat, Leila, additional, Harbord, Nikolas B., additional, Harvey, Elizabeth, additional, Hoenich, Nicholas Andrew, additional, Holmberg, Christer, additional, Holmes, Clifford J., additional, Hootkins, Robert, additional, Hothi, Daljit K., additional, Hou, Susan, additional, Hutchison, Alastair J., additional, Huang, Zhongping, additional, Ing, Todd S., additional, Johnson, Curtis A., additional, Kalantar-Zadeh, Kamyar, additional, Kaplan, André A., additional, Kapoian, Toros, additional, Kaptein, Elaine M., additional, Kathuria, Pranay, additional, Kaufman, Jeffrey L., additional, Keane, William F., additional, Khanna, Ramesh, additional, Khosla, Neenoo, additional, Kimmel, Paul L., additional, Kjellstrand, Carl M., additional, Kooienga, Laura, additional, Kotanko, Peter, additional, Kovalik, Eugene C., additional, Kraemer, Matthias, additional, Langone, Anthony, additional, Lawrence, Peter F., additional, Letteri, Jeffrey J., additional, Leung, Chi-Bon, additional, Levin, Adeera, additional, Levin, Nathan W., additional, Leypoldt, John Kenneth, additional, Li, Philip Kam-Tao, additional, Lindsay, Robert McGregor, additional, Llach, Francisco, additional, MacDougall, Margaret, additional, Mailloux, Lionel U., additional, Martin, Kevin J., additional, Martin, Paul, additional, Massy, Ziad A., additional, McFarlane, Philip A., additional, Mehrotra, Rajnish, additional, Mitsnefes, Mark M., additional, Mittman, Neal, additional, Moritz, Michael J., additional, Mulloy, Laura L., additional, Murphy, Sean W., additional, Negoi, Dana, additional, Neu, Alicia M., additional, Nikakhtar, Bijan, additional, Nissenson, Allen R., additional, Nouri, Pouneh, additional, Nuchtern, Jed G., additional, Oliver, Matthew J., additional, Olyaei, Ali J., additional, Pahl, Madeleine V., additional, Painter, Patricia, additional, Palmer, Biff F., additional, Parfrey, Patrick S., additional, Perilloux, Ashley A., additional, Pham, Phuong-Chi T., additional, Pham, Phuong-Thu T., additional, Pierratos, Andreas, additional, Pittard, Joanne D., additional, Pun, Patrick H., additional, Qvist, Erik, additional, Raj, Dominic S.C., additional, Remuzzi, Giuseppe, additional, Rigatto, Claudio, additional, Rocco, Michael V., additional, Rodriguez, Rudolph A., additional, Ronco, Claudio, additional, Rönnholm, Kai, additional, Rosner, Mitchell H., additional, Sadler, John H., additional, Salusky, Isidro B., additional, Sam, Ramin, additional, Sanchez, Cheryl P., additional, Satko, Scott G., additional, Schaefer, Franz, additional, Schmidt, Rebecca J., additional, Schröder, Cornelis H., additional, Schulman, Gerald, additional, Schwab, Steve J., additional, Schwenk, Michael H., additional, Shapiro, Warren B., additional, Sherman, Richard A., additional, Smith, Jodi M., additional, Somers, Michael J.G., additional, Spanner, Evelyn, additional, Spinowitz, Bruce S., additional, Stivelman, John C., additional, Szeto, Cheuk-Chun, additional, Tannenberg, Alf M., additional, Tipton, Karen B., additional, Traum, Avram Z., additional, Tsai, Arthur, additional, Twardowski, Zbylut J., additional, Tzamaloukas, Antonios H., additional, Vanholder, Raymond, additional, Vaziri, Nosratola D., additional, Wakeen, Maureen, additional, Warady, Bradley A., additional, Ward, Richard A., additional, Wassner, Steven J., additional, Weisbord, Steven D., additional, White, John J., additional, White, Suzanne H., additional, Winchester, James F., additional, Windus, David W., additional, Wish, Jay B., additional, Zappacosta, Anthony R., additional, and Zimmerman, Stephen W., additional

Published
2008
Full Text
View/download PDF

42. Authors’ Reply

Author

Pun, Patrick H., primary, Dupre, Matthew E., additional, Tyson, Clark, additional, Al-Khatib, Sana M., additional, and Granger, Christopher B., additional

Published
2019
Full Text
View/download PDF

47. Chronic kidney disease and arrhythmias : Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Author

Turakhia, Mintu P, Blankestijn, Peter J, Carrero, Juan-Jesus, Clase, Catherine M, Deo, Rajat, Herzog, Charles A, Kasner, Scott E, Passman, Rod S, Pecoits-Filho, Roberto, Reinecke, Holger, Shroff, Gautam R, Zareba, Wojciech, Cheung, Michael, Wheeler, David C, Wanner, Christoph, Winkelmayer, Wolfgang C, Conference Participants, Amann, Kerstin, Banerjee, Debasish, Bansal, Nisha, Boriani, Giuseppe, Bunch, Jared, Chan, Christopher T, Charytan, David M, Conen, David, Friedman, Allon N, Genovesi, Simonetta, Holden, Rachel M, House, Andrew A, Jadoul, Michel, Jardine, Alan G, Johnson, David W, Jun, Min, Labriola, Laura, Mark, Patrick B, McCullough, Peter A, Nolin, Thomas D, Potpara, Tatjana S, Pun, Patrick H, Ribeiro, Antonio L P, Rossignol, Patrick, Shen, Jenny I, Sood, Manish M, Tsukamoto, Yusuke, Wang, Angela Yee-Moon, Weir, Matthew R, Wetmore, James B, Wranicz, Jerzy K, Yamasaki, Hiro, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Turakhia, M, Blankestijn, P, Carrero, J, Clase, C, Deo, R, Herzog, C, Kasner, S, Passman, R, Pecoits-Filho, R, Reinecke, H, Shroff, G, Zareba, W, Cheung, M, Wheeler, D, Winkelmayer, W, Wanner, C, and Genovesi, S

Subjects
Nephrology, Heart rhythm disorders, medicine.medical_treatment, 030232 urology & nephrology, 030204 cardiovascular system & hematology, urologic and male genital diseases, Kidney, law.invention, Sudden cardiac death, 0302 clinical medicine, Randomized controlled trial, law, Risk Factors, atrial fibrillation, Arrhythmia/Electrophysiology, Treatment options, Atrial fibrillation, stroke, Defibrillators, Implantable, Current Opinion, cardiovascular system, Hemodialysis, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, Hypokalemia, arrhythmia, Sudden death, sudden cardiac death, End stage renal disease, 03 medical and health sciences, Renal Dialysis, Internal medicine, Chronic kidney disease, end stage renal disease, arrhythmias, atrial fibrillation, sudden death, medicine, Humans, In patient, cardiovascular diseases, Renal Insufficiency, Chronic, Intensive care medicine, Inflammation, business.industry, Arrhythmias, Cardiac, medicine.disease, Oxidative Stress, Death, Sudden, Cardiac, Potassium, Hyperkalemia, Kidney Failure, Chronic, business, Atrial flutter, chronic kidney disease, 030217 neurology & neurosurgery, Kidney disease
Abstract

Patients with chronic kidney disease (CKD) are predisposed to heart rhythm disorders, including atrial fibrillation (AF)/atrial flutter, supraventricular tachycardias, ventricular arrhythmias, and sudden cardiac death (SCD). While treatment options, including drug, device, and procedural therapies, are available, their use in the setting of CKD is complex and limited. Patients with CKD and end-stage kidney disease (ESKD) have historically been under-represented or excluded from randomized trials of arrhythmia treatment strategies,1 although this situation is changing.2 Cardiovascular society consensus documents have recently identified evidence gaps for treating patients with CKD and heart rhythm disorders.3–7 To identify key issues relevant to the optimal prevention, management, and treatment of arrhythmias and their complications in patients with kidney disease, Kidney Disease: Improving Global Outcomes (KDIGO) convened an international, multidisciplinary Controversies Conference in Berlin, Germany, titled CKD and Arrhythmias in October 2016. The conference agenda and discussion questions are available on the KDIGO website (http://kdigo.org/conferences/ckd-arrhythmias/; 13 February 2018).

Published
2018

49. Apolipoprotein L1 Genetic Variants Are Associated with Chronic Kidney Disease but Not with Cardiovascular Disease in a Population Referred for Cardiac Catheterization

Author

Wang, Hanghang, primary, Pun, Patrick H., additional, Kwee, Lydia, additional, Craig, Damian, additional, Haynes, Carol, additional, Chryst-Ladd, Megan, additional, Svetkey, Laura P., additional, Patel, Uptal D., additional, Hauser, Elizabeth R., additional, Pollak, Martin R., additional, Kraus, William E., additional, and Shah, Svati H., additional

Published
2016
Full Text
View/download PDF

50. Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial

Author

Pun, Patrick H., primary, Abdalla, Safa, additional, Block, Geoffrey A., additional, Chertow, Glenn M., additional, Correa‐Rotter, Ricardo, additional, Dehmel, Bastian, additional, Drüeke, Tilman B., additional, Floege, Jürgen, additional, Goodman, William G., additional, Herzog, Charles A., additional, London, Gerard M., additional, Mahaffey, Kenneth W., additional, Moe, Sharon M., additional, Parfrey, Patrick S., additional, Wheeler, David C., additional, and Middleton, John P., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results